VRCA (Verrica Pharmaceuticals Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by VRCA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-18 | Jayson Rieger | CEO and President | Buy | — | — |
| 2026-08-18 | David Zawitz | Chief Operating Officer | Buy | — | — |
| 2026-08-18 | John J. Kirby | Interim CFO | Buy | — | — |
| 2026-08-18 | Noah L. Rosenberg | CMO | Buy | — | — |
| 2026-06-09 | Jayson Rieger | CEO and President | A | — | — |
| 2026-06-09 | Noah L. Rosenberg | CMO | A | — | — |
| 2026-06-09 | David Zawitz | Chief Operating Officer | A | — | — |
| 2026-06-09 | Lawrence Eichenfield | Director | A | — | — |
| 2026-06-09 | Diem Nguyen | Director | A | — | — |
| 2026-06-09 | MARK A PRYGOCKI SR | Director | A | — | — |
| 2026-06-09 | Gavin Corcoran | Director | A | — | — |
| 2025-12-30 | John J. Kirby | Interim CFO | A | — | — |
| 2025-11-25 | Noah L. Rosenberg | CMO | Buy | — | — |
| 2025-11-25 | John J. Kirby | Interim CFO | Buy | — | — |
| 2025-11-25 | David Zawitz | Chief Operating Officer | Buy | — | — |
| 2025-11-25 | Paul B Manning | Director | Buy | — | — |
| 2025-11-25 | Jayson Rieger | CEO and President | Buy | — | — |
| 2025-06-09 | Gavin Corcoran | Director | A | — | — |
| 2025-06-09 | MARK A PRYGOCKI SR | Director | A | — | — |
| 2025-06-09 | Lawrence Eichenfield | Director | A | — | — |
| 2025-06-09 | Diem Nguyen | Director | A | — | — |
| 2025-04-02 | Gavin Corcoran | Director | A | — | — |
| 2025-03-26 | Noah L. Rosenberg | CMO | A | — | — |
| 2025-03-18 | Jayson Rieger | CEO and President | A | — | — |
| 2025-03-18 | Christopher G. Hayes | CHIEF LEGAL OFFICER | Sell | — | — |
| 2025-02-06 | Gary Goldenberg | Chief Medical Officer | A | — | — |
| 2025-02-06 | Christopher G. Hayes | CHIEF LEGAL OFFICER | A | — | — |
| 2025-02-06 | Ted White | PRESIDENT AND CEO | A | — | — |
| 2025-02-06 | Joe Bonaccorso | CHIEF COMMERCIAL OFFICER | A | — | — |
| 2025-02-06 | Terry Kohler | CHIEF FINANCIAL OFFICER | A | — | — |
| 2024-12-09 | David Zawitz | Chief Operating Officer | A | — | — |
| 2024-11-26 | Jayson Rieger | CEO and President | MIXED | — | — |
| 2024-11-26 | John A Stalfort III | Director | MIXED | — | — |
| 2024-11-26 | Paul B Manning | Director | MIXED | — | — |
| 2024-11-06 | Jayson Rieger | CEO and President | A | — | — |
| 2024-11-06 | John J. Kirby | Interim CFO | A | — | — |
| 2024-10-11 | Christopher G. Hayes | CHIEF LEGAL OFFICER | A | — | — |
| 2024-09-23 | Paul B Manning | Director | G | — | — |
| 2024-08-28 | Joe Bonaccorso | CHIEF COMMERCIAL OFFICER | Sell | — | — |
| 2024-08-28 | Ted White | PRESIDENT AND CEO | Sell | — | — |
| 2024-08-28 | Christopher G. Hayes | CHIEF LEGAL OFFICER | Sell | — | — |
| 2024-08-28 | Gary Goldenberg | Chief Medical Officer | Sell | — | — |
| 2024-08-28 | Terry Kohler | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2024-07-23 | Ted White | PRESIDENT AND CEO | Sell | — | — |
| 2024-07-23 | Joe Bonaccorso | CHIEF COMMERCIAL OFFICER | Sell | — | — |
| 2024-07-23 | Gary Goldenberg | Chief Medical Officer | Sell | — | — |
| 2024-07-23 | Christopher G. Hayes | CHIEF LEGAL OFFICER | Sell | — | — |
| 2024-06-07 | Craig Ballaron | Director | A | — | — |
| 2024-06-07 | Lawrence Eichenfield | Director | A | — | — |
| 2024-06-07 | Diem Nguyen | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 7,306,561 | — |
| — | 10%+ Owner | 709,918 | — |
| — | 10%+ Owner | 672,291 | — |
| — | 10%+ Owner | 503,898 | — |
| — | 10%+ Owner | 256,859 | — |
| — | CEO and President | 202,823 | — |
| — | Director | 187,380 | — |
| — | PRESIDENT AND CEO | 27,879 | — |
| — | Chief Operating Officer | 27,000 | — |
| — | Interim CFO | 23,962 | — |
| — | CHIEF COMMERCIAL OFFICER | 18,774 | — |
| — | CHIEF LEGAL OFFICER | 17,646 | — |
| — | Director | 14,042 | — |
| — | CHIEF FINANCIAL OFFICER | 12,500 | — |
| — | Chief Medical Officer | 12,011 | — |
| — | CMO | 6,557 | — |
| — | Chief Financial Officer | 1,290 | — |
| — | Director | 1,000 | — |
| — | Chief Operating Officer | 850 | — |
| — | Chief Financial Officer | 300 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VRCA quote page; the site-wide leaderboard is on the insider transactions hub.